The transaction includes a 12.2% stake in Cell Design held by Kite Pharma, which Gilead bought for $11.9bn in October this year.
Pharmaceutical producer Gilead Sciences has agreed to acquire US-based cell therapy developer Cell Design Labs in a deal worth up to $567m to help in the development of cancer drugs.
The transaction includes a 12.2% stake in Cell Design held by Kite Pharma, which Gilead bought for $11.9bn in October this year. Citi acted as financial adviser to Cell Design in the sale.
Both Kite and Cell Design focus on chimeric antigen receptors to reprogram a patient’s T cells to…
